Chester County News and Community Website
SPRING HOUSE, PA — Johnson & Johnson presented new data on its investigational treatment, nipocalimab, at the 2025 American Academy of Neurology (AAN) Annual Meeting, providing insight into its potential to …
Johnson & Johnson Showcases Promising Data on Nipocalimab for gMG at AAN Annual Meeting Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has shared promising preliminary results from its Ringer™ PBC IDE study, featured in a presentation at the CTO Plus Conference in New York. The …
Teleflex Reports Promising Preliminary Results for Ringer PBC Study Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced an upcoming conference call and webinar to highlight the latest findings from its pivotal Advance-HTN and Launch-HTN clinical trials. The event …
Mineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment Progress Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biopharmaceutical company, is set to showcase significant advancements in its treatments for Alzheimer’s disease (AD) and Parkinson’s disease (PD) at the …
Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 Read More
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has unveiled promising preclinical and Phase 1 data for ratutrelvir, its investigational oral treatment for COVID-19. Presented at the International Conference for …
Traws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 Treatment Read More WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has unveiled groundbreaking results from the CLEAR study, the first head-to-head randomized controlled trial comparing the UroLift™ System with Rezūm™ Water Vapor Therapy (WVTT) …
Study Highlights UroLift™ System’s Advantages Over Rezūm™ in Treating BPH Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company, shared its financial results for 2024 and provided a progress update on its lead programs aimed at advancing cancer …
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations Read More
PHILADELPHIA, PA — iECURE, Inc. recently unveiled encouraging early data from its ongoing OTC-HOPE Phase 1/2 study at the 2025 ACMG Annual Clinical Genetics Meeting. The study, which evaluates the …
iECURE Highlights Promising Results from OTC-HOPE Study at 2025 ACMG Genetics Meeting Read More
WILMINGTON, DE — Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials evaluating povorcitinib, an oral JAK1 inhibitor, for moderate to severe hidradenitis suppurativa …
Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has shared its corporate updates and financial results for the fourth quarter and full year of 2024, highlighting significant advancements in its clinical …
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position Read More